Participants, left to right: Ken Schultz, Trethera Inc; Steve Rosen, City of Hope; Beth Seidenberg, Westlake Village BioPartners; Amir Naiberg, UCLA Technology Development Group; Arie Belldegrun, Allogene Therapeutics; William Looney, In Vivo; Mike Jung, UCLA Chemistry Dept; Monica Schmiede, Informa Pharma Intelligence; David Reese, Amgen. Not pictured: Peter Moglia, Alexandria Real Estate Equities.
Building The Biotech City: Is Los Angeles The Go-To Destination For Tomorrow’s Drug Innovations?
Round Table Discussion: Positioning Los Angeles As The Next Big Biotech Hub
The complexity of producing viable drug candidates is increasing as an abundance of new science keeps extending the range of possible targets and fragmenting disease subtypes. Proximity to novel exploratory research is a driver of pipeline productivity – so can physical location within a communal geography of well-resourced intellectual firepower raise the odds for R&D success? In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.
More from Growth
More from In Vivo
• By
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
• By
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
• By
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.